Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to
your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Appointment
- Clinical Senior Research Fellow
- Research Department of Haematology
- Cancer Institute
- Faculty of Medical Sciences
Biography
Dr Maciocia is a consultant haematologist and clinician scientist specialising in chimeric antigen receptor T cell therapy for cancer. He undertook training in medicine and pharmacology at the Univerity of Edinburgh, followed by clinical training in medicine and haematology in Edinburgh, Bristol/ Bath, Zambia and London. He completed his PhD in CAR-T cell therapy for T cell lymphoma in the laboratory of Dr Martin Pule at UCL, in 2017, and completed clinical training in 2019. He now sees patients in the CAR-T clinic at UCLH while running a laboratory group based at UCL Cancer Institute.
Dr Maciocia is currently funded by Cancer Research UK as a clinician scientist fellow.
Research Themes
See More
See LessResearch Summary
The Maciocia laboratory is focussed on the preclinical and clinical development of chimeric antigen receptor (CAR)-T cells for cancer. Major areas of focus include:
- development of allogeneic 'off the shelf' CAR-T cell therapies. We utilise protein-based techniques which avoid the costs and complexities of genome editing, to attempt to deliver safe and effective allogeneic CAR-T. An MRC-funded phase 1 clinical trial based upon this work will open December 2022.
- development of CAR-T approaches for T cell malignancies. Treatment of T cell malignancies with immunotherapy is challenging due to shared target expression between malignant and normal T cells. Despite this, the Maciocia lab have identified targtes in several disorders leading to 2 phase 1 trials currently recruiting (anti-TRBC1 CAR-T for T cell lymphomas, Autolus) or in setup (anti-CCR9 CAR-T for T cell acute lymphoblastic leukaemia, MRC).
- T cell engineering to enhance efficacy. Multiple projects are in place with foci on CAR-T persistence, recruitement of non-CAR immune cells and the immunosuppressive TME.
- CAR-T for new disease indications. We are interested in developing CAR-T for new solid cancer and non-cancerous targets.
Major UCL collaborators include
- Martin Pule
- Claire Roddie
- Lydia Lee
- Marc Mansour
Teaching Summary
Dr Maciocia teaches on the Cancer MSc program at UCL, and also delivers teaching to UCL medical students and to postgraduates on Masters programs at ICH. He supervises multiple PhD and undergraduate/ Masters students.
Appointments
| 01-AUG-2021 – 01-AUG-2026 | CRUK Clinician Scientist | Haematology | Cancer Institute, United Kingdom |
